Recursion Pharmaceuticals, Inc. RXRX Accrued development expense
Accrued development expense at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rxrx:IncreaseDecreaseInAccruedDevelopmentExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s accrued development expense?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued development expense of $730K in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s accrued development expense changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accrued development expense increased by 21.9% year-over-year, from $599K to $730K.
- What does accrued development expense mean?
- Measures the change in liabilities related to research and development activities that have been incurred but not yet paid. This metric provides insight into the timing of R&D cash outflows and the company's management of vendor and partner payment cycles.